Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs

 

An image of a doctor working on a laptop.

Rapid Priority Setting in Low- and Middle-Income Countries: The Potential of Adaptive Health Technology Assessments

Health budgets are limited and decision makers in all countries face very challenging decisions about which health interventions will be provided, and which will not. COVID has only added to this pressing priority setting problem. In this blog, we highlight key takeaways from our recent commentary in the BMJ Global Health, where we make the case for “adaptive health technology assessment,” or “aHTA.”

A figure of the summary of costs and consequences to consider in COVID-19 vaccine HTA.

Who Gets a COVID-19 Vaccine and Who Pays? The Need for Economic Analysis

In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the best possible decisions in bringing the pandemic under control, particularly in low-and middle-income countries (LMICs). In this blog we look at the potential of HTA to inform how much vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.

Caduceus symbol as a pair of scales for weighing

Afro-European Partnerships in Health: Accelerating Better Efficiency of Health Spending

In the wake of the COVID-19 crisis, many sub-Saharan African countries will face serious economic crises and shrinking public spending. If countries are unable to spend more, they need to spend better. Europe has leading expertise in building institutions for priority-setting in health, making it an obvious potential source for collaboration with the Global South.

A close-up of some pills

Healthcare Technologies and COVID-19: Speed is Not Always a Good Thing

With a focus on tests, treatments, and a vaccine, we take a look at the emerging global clinical and economic evidence-base underpinning some of these technologies, the mechanisms (mostly global) for financing these commodities, and, finally, the decision-making processes for selecting technologies. This includes identifying the right subpopulations and negotiating a cost-effective tiered price across countries and regions.